Anna Rose Welch

Anna Rose Welch

Anna R. Welch is the executive editor for Biosimilar Development.com. She writes features on the latest news, issues, and trends in the biosimilar industry.

ARTICLES BY ANNA ROSE

  • Top 5 Biosimilar Developments Of 2016
    Top 5 Biosimilar Developments Of 2016

    In the spirit of this list-making season, I compiled what I thought were the five most important biosimilar-related triumphs in the past year. Many of these events were widely covered by the media and will play an influential role in how the biosimilar industry unfolds through 2017 and beyond.

  • The Case For Moving The EMA To Ireland
    The Case For Moving The EMA To Ireland

    Relocating an organization as large as the EMA, which employs upwards of 1,000 people in London, will be no easy feat. As such, IDA Ireland, an agency that supports companies in Ireland and promotes foreign direct investments in the country, is working to compile information on why Ireland would be a good location for the EMA.

  • Will Teva’s Play Usher Generic, Biosimilar Makers Into “Innovator” Territory?
    Will Teva’s Play Usher Generic, Biosimilar Makers Into “Innovator” Territory?

    PhRMA is facing a controversial, potentially industry-altering decision. The generics king Teva has requested to become a member of the trade organization that traditionally represents “innovators”. Could this move redefine the industry's perception of "innovation"?

  • What Biosimilars Can Learn From The Diamond Industry
    What Biosimilars Can Learn From The Diamond Industry

    Not only are there some fascinating parallels between the fledging biosimilar and lab-grown diamond industries, but there are also some lessons biosimilar makers can take away from the development and commercialization of lab-grown diamonds.

  • Could Value-Based Pricing Be Yet Another Roadblock To Biosimilar Uptake?
    Could Value-Based Pricing Be Yet Another Roadblock To Biosimilar Uptake?

    As pay-for-performance drugs becomes more high-profile in the U.S., these emerging deals pose a number of difficulties for reference makers. But if pay-for-performance becomes more wide-spread, could innovators' successes become yet another roadblock to getting biosimilars into doctor's treatment repertoire and patients' hands?

  • EPIRUS Biopharmaceuticals: What Biosimilars Can Learn From The Generics Market
    EPIRUS Biopharmaceuticals: What Biosimilars Can Learn From The Generics Market

    Though differentiating large-molecule biosimilars from small molecule generics is a staple in biosimilar education, Amit Munshi, CEO of pure-play biosimilar company EPIRUS Biopharmaceuticals, argues the history of the generics market could hold valuable clues as to how the biosimilar market will evolve.

  • The Generic And Biosimilar Markets: Are They Really That Different?
    The Generic And Biosimilar Markets: Are They Really That Different?

    As the FDA continues to compose guidances on the labeling and interchangeability of biosimilar medicines, there remains one big, overarching concern in the industry, and that is making sure biosimilar medicines are not treated as small molecule generics. But should we really be considering the two types of drugs as drastically different as we have been over the past few months?

  • Could 96 Percent FDA Drug Approval Rate Harm Biosimilar Market?
    Could 96 Percent FDA Drug Approval Rate Harm Biosimilar Market?

    Last week, Matthew Herper of Forbes published an eye-opening article providing a closer look at FDA approvals in recent years, coming to the conclusion that the industry is facing what could be a dangerously high approval rate for new drugs. But how could high approval rates be a bad thing?

  • Could Birth Of “Big Generic” Be Foreshadowing “Big Biosimilar?”
    Could Birth Of “Big Generic” Be Foreshadowing “Big Biosimilar?”

    In 2015, the generics market saw several players jump ship and one company grow significantly — and to some, alarmingly — larger. If buyers are consolidating and causing generics companies to consolidate, isn’t it natural to expect a similar trend to hit the biosimilars market when it’s more established?

  • TPP Negotiations Stall, Hold Back Biosimilars Market
    TPP Negotiations Stall, Hold Back Biosimilars Market

    As if the biosimilar naming debate between brand-name pharmaceutical companies and generic drugmakers wasn’t enough, these two sides continue to challenge each other — this time, over biologics data exclusivity in the ongoing Trans-Pacific Partnership (TPP) negotiations.

More From Anna Rose Welch